​

Roivant Sciences (ROIV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ROIV Stock Forecast

Roivant Sciences (ROIV) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $15.50, with a high of $17.00 and a low of $12.50. This represents a 39.26% increase from the last price of $11.13.

$10 $11 $12 $13 $14 $15 $16 $17 High: $17 Avg: $15.5 Low: $12.5 Last Closed Price: $11.13

ROIV Stock Rating

Roivant Sciences stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (90.00%), 1 Hold (10.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 1 9 Strong Sell Sell Hold Buy Strong Buy

ROIV Forecast vs Benchmarks

TypeNameUpside
StockRoivant Sciences39.26%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--8
Avg Price Target--$16.69
Last Closing Price$11.13$11.13$11.13
Upside/Downside--49.96%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25361--10
Dec, 24461--11
Nov, 24461--11
Oct, 24461--11
Sep, 24461--11
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 21, 2024David RisingerLeerink Partners$17.00$11.9242.62%52.74%
Sep 19, 2024Corinne JenkinsGoldman Sachs$17.00$12.0640.96%52.74%
Sep 11, 2024Chi FongBank of America Securities$12.50$12.460.32%12.31%
May 31, 2024Allison BratzelPiper Sandler$20.00$10.3992.49%79.69%
Apr 03, 2024Douglas TsaoH.C. Wainwright$18.00$10.9264.84%61.73%
Apr 03, 2024Neena Bitritto-GargDeutsche Bank$15.00$10.9237.36%34.77%
Apr 02, 2024Corinne JenkinsGoldman Sachs$18.00$10.9264.84%61.73%
Mar 13, 2024Corinne JenkinsGoldman Sachs$16.00$10.6250.66%43.76%
Jan 05, 2023Citigroup$14.00$7.5685.19%25.79%
Dec 19, 2022Leerink Partners$10.00$7.3236.61%-10.15%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Oct 21, 2024Leerink PartnersOutperformOutperformhold
Sep 19, 2024Goldman SachsBuyBuyhold
Sep 11, 2024H.C. WainwrightUnderperformUnderperformhold
Sep 11, 2024Cowen & Co.BuyBuyhold
Sep 11, 2024H.C. WainwrightBuyBuyhold
Sep 11, 2024Bank of America SecuritiesNeutralNeutralhold
Jul 10, 2024Piper SandlerOverweightOverweighthold
May 31, 2024Goldman SachsUnderperformUnderperformhold
May 31, 2024Piper SandlerOverweightOverweighthold
May 30, 2024Cantor FitzgeraldOverweightOverweighthold

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 $3 $4 $5 $6 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-1.73$5.55-----
Avg Forecast$-1.59$5.22$-0.77$-1.09$-1.07$-0.47$0.20
High Forecast$-2.63$4.98$-0.81$-1.29$-1.39$-0.77$0.09
Low Forecast$-0.73$5.41$-0.72$-0.81$-0.82$-0.22$0.33
Surprise %8.81%6.32%-----

Revenue Forecast

$0 $500M $1B $2B $2B $3B Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$61.28M$124.80M-----
Avg Forecast$52.28M$181.74M$92.10M$34.74M$61.48M$762.32M$1.57B
High Forecast$30.60M$176.37M$56.33M$17.27M$35.98M$446.16M$920.09M
Low Forecast$78.79M$193.36M$139.48M$59.09M$92.67M$1.15B$2.37B
Surprise %17.22%-31.33%-----

Net Income Forecast

$-3B $-1B $300M $2B $3B $5B Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-1.23B$4.35B-----
Avg Forecast$-1.32B$4.35B$-605.08M$-804.05M$-911.26M$-387.83M$163.44M
High Forecast$-2.19B$4.14B$-670.75M$-1.07B$-1.15B$-643.57M$75.32M
Low Forecast$-608.11M$4.50B$-596.22M$-672.44M$-682.96M$-178.73M$271.22M
Surprise %-6.78%-0.07%-----

ROIV Forecast FAQ

Is Roivant Sciences stock a buy?

Roivant Sciences stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Roivant Sciences is a favorable investment for most analysts.

What is Roivant Sciences's price target?

Roivant Sciences's price target, set by 10 Wall Street analysts, averages $15.5 over the next 12 months. The price target range spans from $12.5 at the low end to $17 at the high end, suggesting a potential 39.26% change from the previous close price of $11.13.

How does Roivant Sciences stock forecast compare to the average forecast of its sector, industry, and investment themes?

Roivant Sciences stock forecast shows a 39.26% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Roivant Sciences over the past three months?

  • January 2025: 30.00% Strong Buy, 60.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 36.36% Strong Buy, 54.55% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 36.36% Strong Buy, 54.55% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.

What is Roivant Sciences’s EPS forecast?

Roivant Sciences's average annual EPS forecast for its fiscal year ending in March is -0.77 for 2025, a -113.87% decrease from the reported $5.55 in 2024. The prediction for 2026 is $-1.09, $-1.07 for 2027, $-0.47 for 2028, and $0.2 for 2029.

What is Roivant Sciences’s revenue forecast?

Roivant Sciences's average annual revenue forecast for its fiscal year ending in March is $92.1M for 2025, a -26.20% decrease from the reported $124.8M in 2024. The forecast for 2026 is $34.74M, $61.48M for 2027, $762.32M for 2028, and $1.57B for 2029.

What is Roivant Sciences’s net income forecast?

For its fiscal year ending in March, Roivant Sciences's average annual net income forecast is $-605M for 2025, reflecting a -113.91% decrease from the reported $4.35B in 2024. The projection for 2026 is $-804M, $-911M for 2027, $-388M for 2028, and $163.44M for 2029.